Atara Biotherapeutics (ATRA) Given Buy Rating at Mizuho

Mizuho reaffirmed their buy rating on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a report published on Sunday morning, AnalystRatings.com reports. Mizuho currently has a $62.00 price target on the biotechnology company’s stock.

A number of other equities analysts have also recently weighed in on the stock. ValuEngine cut shares of Atara Biotherapeutics from a strong-buy rating to a buy rating in a research report on Wednesday, April 10th. William Blair reissued an outperform rating on shares of Atara Biotherapeutics in a research report on Monday, April 1st. BidaskClub raised shares of Atara Biotherapeutics from a hold rating to a buy rating in a research report on Thursday, February 7th. Cowen reissued a buy rating on shares of Atara Biotherapeutics in a research report on Tuesday, February 26th. Finally, Zacks Investment Research cut shares of Atara Biotherapeutics from a hold rating to a sell rating in a research report on Monday, March 4th. Three research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $49.00.

Shares of NASDAQ ATRA opened at $31.86 on Friday. The firm has a market cap of $1.47 billion, a PE ratio of -6.05 and a beta of 2.25. Atara Biotherapeutics has a twelve month low of $27.85 and a twelve month high of $54.45.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Tuesday, February 26th. The biotechnology company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.44). On average, research analysts anticipate that Atara Biotherapeutics will post -5.99 EPS for the current year.

In related news, Director Joel S. Marcus sold 62,590 shares of the business’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $36.07, for a total value of $2,257,621.30. Following the sale, the director now directly owns 32,590 shares of the company’s stock, valued at approximately $1,175,521.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Isaac E. Ciechanover sold 7,800 shares of the business’s stock in a transaction on Thursday, January 24th. The shares were sold at an average price of $35.06, for a total transaction of $273,468.00. Following the completion of the sale, the chief executive officer now directly owns 433,111 shares in the company, valued at $15,184,871.66. The disclosure for this sale can be found here. Insiders sold a total of 162,524 shares of company stock worth $6,069,971 over the last ninety days. 10.60% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC bought a new stake in Atara Biotherapeutics during the 3rd quarter worth about $108,000. BlackRock Inc. lifted its position in Atara Biotherapeutics by 3.8% during the 3rd quarter. BlackRock Inc. now owns 3,490,782 shares of the biotechnology company’s stock worth $144,345,000 after buying an additional 126,178 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Atara Biotherapeutics by 1,801.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 229,141 shares of the biotechnology company’s stock worth $9,474,000 after buying an additional 217,088 shares in the last quarter. Tower Research Capital LLC TRC bought a new stake in Atara Biotherapeutics during the 3rd quarter worth about $103,000. Finally, JPMorgan Chase & Co. lifted its position in Atara Biotherapeutics by 35.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,202,912 shares of the biotechnology company’s stock worth $49,741,000 after buying an additional 315,921 shares in the last quarter.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

See Also: What is the balance sheet?

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.